PCSK9 inhibitors Archives

Merck’s Anti-Cholesterol Drug Threatens Esperion, Other PCSK9 Inhibitor Makers

Cholesterol, Forecasts, Merck, PCSK9 inhibitors, R&D, Therapeutics

As a class of drugs to treat high cholesterol, PCSK9 inhibitors have had trouble gaining tracking in the marketplace.

November 15, 2021/by BioSpace

Court Rules Against Amgen PCSK9 Patent Claims Against Sanofi and Regeneron

"Bad" LDL Cholesterol, Amgen, Blockbusters, Business, Cholesterol, Federal Courts, Patent Claims, PCSK9 inhibitors, Regeneron Pharmaceuticals, Rivalries, Sanofi, Therapeutics, U.S. Court Of Appeals

In a long-running court battle over PCSK9 antibodies, Amgen lost the company’s bid to uphold patent claims for the cholesterol drug Repatha against rival drug Praluent, developed by Sanofi and Regeneron.

February 12, 2021/by Andrew Humphreys

Could These Drugs Become Blockbusters in the Next 4 Years?

Antibody-Drug Conjugates (ADCs), Blood Transfusions, Breast Cancer, Business, FDA, Migraine, Multiple Sclerosis, New Drug Applications, PCSK9 inhibitors, Potential Blockbusters, R&D, RNA, TROP-2, Type 2 Diabetes

Clarivate Analytics pegged 11 drugs set to enter the market during 2020 as potential blockbusters by 2024

February 18, 2020/by BioSpace

Researchers Develop Nanoparticles to Eat Plaques that Cause Heart Attacks and Strokes

Arteries, Atherosclerosis, Cardiovascular Events, Heart Attacks, Michigan State University, Nanoparticles, Nature Nanotechnology, PCSK9 inhibitors, Plaque, R&D, Researchers, Stanford University, Stroke

Researchers developed a type of nanoparticle that can “eat debris” related to the plaques that cause heart attacks.

January 29, 2020/by BioSpace

Will 2020 Be a Hot Deal Year for Biopharma?

Acquisitions, Analysts, Biopharma, Business, Deals, Diagnostics, Medical Devices, Partnerships, PCSK9 inhibitors

Some analysts are checking their crystal balls to get an idea if 2020 will be a busy year for investors, and the early thinking on biotech is yes.

November 26, 2019/by BioSpace

FDA approves expanded label for Praluent

"Bad" LDL Cholesterol, Approvals, Biotech, Cardiovascular Events, Cholesterol, Drug Pricing, Expanded Label, FDA, FDA/Regulatory, Heart Attacks, Heterozygous Familial Hypercholesterolemia (HeFH), Injectables, Major Adverse Cardiovascular Events (MACE), PCSK9 inhibitors, Statins, Stroke

The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals’ cholesterol drug Praluent as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.

April 26, 2019/by Reuters Health

Why Pharma Must Change Its Model

Cholesterol, FDA/Regulatory, Health, Hepatitis, Innovation, PCSK9 inhibitors, Pharma, R&D, Therapeutics

A difficult feat to accomplish in business is to make dramatic change in the midst of current success. History is littered with companies that were once on top of the […]

July 31, 2015/by Forbes Health

Amgen Raises 2015 Outlook, Results Beat Expectations

Analysts, Approvals, Biotech, Business, FDA/Regulatory, Forecasts, Health, PCSK9 inhibitors, People on the Move, Pricing, Quarterly results, R&D, Therapeutics, Wall Street

Amgen Inc. raised its 2015 guidance after reporting that its second-quarter earnings rose 6.9% on better-than-expected sales growth and lower operating expenses. For the year, the biotechnology company now expects […]

July 30, 2015/by Wall Street Journal Health

Pricey Drugs Largely To Blame For Uptick In National Health Expenditures

ACA, Centers for Medicare and Medicaid Services (CMS), Health, Healthcare, Hepatitis, PCSK9 inhibitors, Pricing, Therapeutics

What do you get when you combine Obamacare with an expected explosion in the use of pricey drugs and the rapid aging of the Baby Boomer population? The answer, courtesy […]

July 28, 2015/by Forbes Health